Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
No side effects, lost about 6lbs in 4 weeks
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
Data confirmed the findings from the previous trial
A supportive approach to your energy and weight goals Natural energy levels Healthy metabolism Focus and clarity Complements GLP-1 programs May regulate appetite Safe, non-stimulant option Fat metabolism Shed journey 3-minute signup, 100% online Receive a personalized plan
The most frequently cited mechanistic findings come from a small group of obese-rodent studies published around the beginning of the 2000s
US$ 28.56
US$ 22.43
US$ 27.97
US$ 24.97
US$ 26.34
US$ 21.54
